Warning letter links deaths to drugs

Brown, William
July 1991
New Scientist;7/27/91, Vol. 131 Issue 1779, p15
Reports on the confidential letter sent by German pharmaceutical company Boehringer Ingelheim warning about increased risk of death from asthma from exhalation of their beta-2 agonists. Beta-2 agonists as mainstay of asthma treatment; Warning sent to authorities before full publication of results of a study; Inquiry launched earlier by the Department of Health.


Related Articles

  • Oesophageal ulcer reported in Pradaxa recipients.  // Reactions Weekly;Oct2013, Issue 1475, p2 

    The article reports that Boehringer Ingelheim GmbH has reported cases of oesophageal ulcers in patients who received Pradaxa drug.

  • Pharma: Other News To Note.  // BioWorld Today;11/14/2013, Vol. 24 Issue 220, p7 

    The article reports on the application submitted by Boehringer Ingelheim GmbH to extend the indication for the use of tiotropium (Spiriva) Respimat to the treatment of asthma in adults, in November 2013.

  • Pharma: Clinic Roundup.  // BioWorld Today;9/5/2012, Vol. 23 Issue 172, p7 

    The article reports on Phase III trial data released by Boehringer Ingelheim GmbH which indicates that tiotropium delivered by the Respimat Soft Mist Inhaler led to significant improvements in lung function in adults with asthma.

  • BI puts non-profit at the wheel of COPD campaign. Weinstein, Deborah // Medical Marketing & Media;May2012, Vol. 47 Issue 5, p28 

    The article reports on the move of Boehringer Ingelheim GmbH which handed over its public health initiative on chronic obstructive pulmonary disease (COPD) Drive4COPD to the nonprofit organization COPD Foundation, however it will still provide financial support.

  • US FDA informs public of Viramune hepatotoxicity.  // Reactions Weekly;1/29/2005, Issue 1036, p2 

    Reports on the issuance of a public health advisory by the U.S. Food and Drug Administration regarding the risk of hepatotoxicity with long-term use of the Viramune label, as of January 2005. Background on a related letter issued by Boehringer Ingelheim for health care professionals;...

  • RESPIRATORY TRACT.  // Monthly Prescribing Reference;Apr2011, Vol. 27 Issue 4, p327 

    The article presents the drugs for different types of respiratory tract disorders. They include GlaxoSmithKline's Advair Diskus 100/50 for asthma, Boehringer Ingelheim GmbH's Atrovent HFA for bronchospasm associated with chronic bronchitis and emphysema, and Daiichi Sankyo Inc.'s Evoxac for dry...

  • HYPERTENSION TREATMENTS: ORAL CCBs.  // Monthly Prescribing Reference;May2015, Vol. 31 Issue 5, p36 

    The article offers information on the oral calcium channel blockers (CCBs) for treatment of hypertension, such as benzothiazepines, dihydrophyridines, and diphenylalkylamines. Also provided are the precautions, interactions, and adverse reactions for micardis and micardis hydrochlorothiazide...

  • Dabigatran 1 year later.  // Pharmacy Today;Oct2011, Vol. 17 Issue 10, p54 

    The article focuses on various issues related to the Dabigatran (Pradaxa), an oral anticoagulant from Boehringer Ingelheim GmbH. It says that the company reported that 250,000 patients were already taking the drug in the U.S. by late August 2011. Meanwhile, it states that some clinicians are...

  • US labelling for Flomax warns of Intraoperative Floppy Iris Syndrome.  // Reactions Weekly;12/3/2005, Issue 1080, p2 

    The article reports on the inclusion of Intraoperative Floppy Iris Syndrome in the label of Flomax. According to a letter issued by Boehringer Ingelheim, during phacoemulsification cataract surgery in patients treated with alpha 1 adrenoceptor antagonists Intraoperative Floppy Iris Syndrome was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics